EWTX
Edgewise Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Edgewise Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
No other changes.
No other changes.
Edgewise Therapeutics, Inc.
37.69
−0.42 · −1.10%
post 37.69 0.00%
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
Inputs8Q avg ±2.4%·×2.52·rich
straddle ±12.0%
spot 38.15exp Nov 20ATM strike 38ATM straddle 5.40IV 83%
−1.27%
vs ±11.6% implied · ×0.11
shaded = implied · ▲▼ = realized
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Edgewise Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Edgewise Therapeutics, Inc.'s 6 closest co-movers, none share that code.
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
—
—
Largest filed tie
—
| Manager | Value | % base | |
|---|---|---|---|
| Orbimed | $630.5M | 12.96% | 0.00% |
| Paradigm Biocapital | $415.1M | 8.53% | +38.70% |
| RA Capital Management | $341.0M | 7.01% | −19.52% |
| BlackRockindex-like | $268.4M | 5.52% | +2.06% |
| Jupiter Topco | $246.9M | 5.08% | — |
| Manager | Value | % base | |
|---|---|---|---|
| Orbimed | $630.5M | 12.96% | 0.00% |
| Paradigm Biocapital | $415.1M | 8.53% | +38.70% |
| RA Capital Management | $341.0M | 7.01% | −19.52% |
| BlackRockindex-like | $268.4M | 5.52% | +2.06% |
| Jupiter Topco | $246.9M | 5.08% | — |
Bull2
Bear1